Bayer Pharmaceuticals Corporation (CT)/Onyx Pharmaceuticals, Inc. Report Success in Asian Trial for Nexavar

Published: Aug 30, 2007

Liver Cancer Test Stopped Early August 29, 2007 – Bayer and Onyx put an early stop to a Phase III trial of Nexavar in Asia-Pacific patients because of positive results. The trial was conducted among patients with hepatocellular carcinoma, the most common form of liver cancer. Nexavar extended all measures of survival. Asian regulators asked for the trial as a supplement to the filing for approval of Nexavar to prove the drug was safe and effective in this particular population. More details...

Back to news